Colistin Market Demand, Size & Forecast by 2034

The colistin market size is projected to reach US$ 510.94 million by 2034 from US$ 337.00 million in 2025. The market is expected to register a CAGR of 4.8% during 2026–2034. 

Colistin Market Analysis

Market growth is driven by an increase in multidrug-resistant Gram-negative infections, sustained veterinary demand in livestock and poultry farming, and regulatory shifts and policies addressing antimicrobial resistance. Advancements in inhaled colistin formulations for respiratory infections and expansion of combination therapies for multidrug-resistant infections are expected to create ample market opportunities.

Colistin Market Overview

Rising rates of multidrug-resistant bacterial infections have led to increased demand for colistin, highlighting its role as a last-line antibiotic in critical care settings. Colistin is generally used to treat severe infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa or Acinetobacter baumannii, when other antibiotics have failed. Due to the high frequency of hospital-acquired infections, hospitals and intensive care units are expected to remain the primary end users of colistin. Market growth is expected to be supported by increasing knowledge about antimicrobial resistance, a growing number of individuals being hospitalized, and improvements in healthcare infrastructure in developing regions.

Colistin Market: Strategic Insights

Colistin Market Drivers and Opportunities

Market Drivers:

• Increased Multidrug-Resistant Gram-Negative Infections in Human Healthcare: The rise of multidrug-resistant Gram-negative infections, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, has led to increased reliance on colistin, a last-resort antibiotic, for the treatment of severe nosocomial infections such as sepsis and ventilator-associated pneumonia.
• Sustained Veterinary Demand in Livestock and Poultry Farming: Colistin continues to be used off-label in poultry and swine farming for control of Gram-negative infections—such as E. coli and Salmonella—to promote animal health and production, despite the presence of increasing regulatory restrictions and concerns regarding increasing antimicrobial resistance.
• Regulatory Shifts and Policies Addressing Antimicrobial Resistance: New global regulations restricting the non-therapeutic use of colistin in agriculture are reshaping the market by reducing the amount of colistin consumed in livestock. These regulations are redirecting its supply toward regulated veterinary uses and the treatment of critically important human infections caused by multidrug-resistant organisms​‍‌​‍​‌.

Market Opportunities:

• Advancements in Inhaled Colistin Formulations for Respiratory Infections: Advances in the formulations of inhaled colistin have allowed for better targeting of the lungs. These advancements make colistin more effective by providing colistin to the lung tissue with less systemic toxicity, improving compliance, and allowing for clinical trials to be conducted to expand the use of colistin in other disease states.
• Expansion of Combination Therapies for Multidrug-Resistant Infections: The concurrent use of colistin with other classes of antibiotics such as meropenem, tigecycline, and fosfomycin has improved efficacy of treating the infected person, decreased the chance of developing resistance, and assisted in developing optimized regimens.
• Regional Market Expansion in Asia Pacific amid Rising Antimicrobial Resistance: The increasing rate of antimicrobial resistance, growth of healthcare infrastructures, intensive livestock farming, and the growing use of last-resort antibiotics in Asia Pacific create tremendous opportunities for increasing the use of colistin for both regulated human and veterinary medicine.

Colistin Market Report Segmentation Analysis

The colistin market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in most industry reports:

By Formulation:

• Oral: Colistin is administered orally primarily for veterinary purposes to control gastrointestinal infections in livestock, particularly in the production of poultry and swine.
•  Injectables (IV or IM): Colistin is used intravenously and subcutaneously for the treatment of severe multi-drug-resistant Gram-negative infections, particularly sepsis, pneumonia, and bloodstream infections.
• Topical Formulations: Colistin is also used topically to treat localized skin, wound, and ear infections due to susceptible Gram-negative bacteria.
• Inhalation Solutions: Inhalation solutions containing colistin are used to provide high concentrations of the drug directly to the lungs. They are used as a standard treatment for cystic fibrosis or chronic respiratory infections caused by Pseudomonas.

By Indication:

• Human Health
• Animal Health

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Channel
• Other Distribution Channel

By Geography:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Colistin Market Players Density: Understanding Its Impact on Business Dynamics

The Colistin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Colistin Market Share Analysis by Geography

Asia Pacific is expected to grow at the fastest rate during the forecast period. The increasing prevalence of multidrug-resistant Gram-negative infections in hospitals, along with increasing demand from the animal health industry, is likely to drive the market. Emerging markets in Latin America, the Middle East, and Africa also have several untapped market opportunities.

The colistin market grows differently across regions, driven by economic growth and rising healthcare expenditure. Below is a summary of market share and trends by region:

1. North America

• Market Share: Holds a significant portion of the global market
• Key Drivers:
  • Increased incidence of hospital-acquired multidrug-resistant Gram-negative infections, along with improvements in the healthcare environment
• Trends: Increase in the number of healthcare providers participating in antimicrobial stewardship programs

2. Europe

• Market Share: Substantial share due to early adoption of colistin models
• Key Drivers:
  • Strict implementation of antimicrobial stewardship strategies, along with the increasing number of MDR infections
• Trends: Stringent Regulation for Colistin through strict prescription controls, hospital monitoring programs, and guideline-based use to minimize the occurrence of antimicrobial resistance.

3. Asia Pacific

• Market Share: Fastest-growing region with an annually rising market share
• Key Drivers:
  • A growing population with high rates of antimicrobial resistance, coupled with ongoing improvements in healthcare systems in the region.
• Trends: Increasing incidence of multidrug-resistant (MDR) Gram-negative bacteria, alongside the development of antimicrobial stewardship programs and the implementation of regulated veterinary use of colistin.

4. South and Central America

• Market Share: Steadily progressing market share
• Key Drivers:
  • An increasing prevalence of antibiotic-resistant infections
• Trends: Increasing number of hospitals using colistin to treat resistant infections

5. Middle East and Africa

• Market Share: Small market share, growing at a rapid pace
• Key Drivers:
  • Increased prevalence of infectious diseases and ongoing improvements in healthcare access
• Trends: Growing reliance on colistin for the treatment of serious hospital infections

High Market Density and Competition

Competition is strong due to the presence of established players, such as Xellia Pharmaceuticals, Livzon Pharmaceutical Group, and Zhejiang Apeloa Kangyu Pharmaceutical.

This high level of competition urges companies to stand out by offering:

• Advanced security features
• Competitive pricing models
• Strong customer support and easy integration

Opportunities and Strategic Moves

• To comply with international antimicrobial stewardship standards, producers are implementing regulations that require the responsible use of colistin in both human and veterinary medicine. Key players are increasing their production capacity for active pharmaceutical ingredients (APIs) and enhancing their distribution methods.
• Pharmaceutical companies can explore combining colistin with other antibiotics to enhance therapy for multidrug-resistant infections. Manufacturers are seeing opportunities for colistin use due to rising antimicrobial resistance and the ongoing development of healthcare systems in parts of the Asia Pacific, Latin America, and Africa.

Other companies analysed during the course of research:

• Meiji Seika Pharma
• SNA Health Care
• Fengchen Group
• Sinopharm Group
• Clearsynth
• JSN Chemicals
• HBCChem
• Kaken Pharmaceutical
• Hebei Veyong Pharmaceutical
• Jiangsu SEL Biochem
• Qingdao Qingmei Biotech
• Yichang Sanxia Pharmaceutical
• Tocopharm
• Anhui Sinotech Industrial
• Grand Health Industrial
• Pfizer
• Merck & Co.
• Cipla
• Fresenius Kabi
• Teva Pharmaceutical Industries
• Hikma Pharmaceuticals
• Wockhardt

Colistin Market News and Recent Developments

• In February 2024, PureIMS’ product Colistin Cyclops received Orphan Drug Designation from the FDA and EMA for treating cystic fibrosis (CF). This dry powder inhaler targets Pseudomonas aeruginosa infections.

• In January 2024, Bio-Labs developed Colinext (colistimethate) 1 MIU to meet the growing demand for emerging antibiotics in the market. It is used to treat infections caused by Gram-negative bacteria that are highly resistant to conventional therapies.

Colistin Market Report Coverage and Deliverables

The "Colistin Market Size and Forecast (2021–2034)" report provides a detailed analysis of the market covering below areas:

• Colistin Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Colistin Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Colistin Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Colistin Market
• Detailed company profiles